{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T07:53:52Z","timestamp":1774511632451,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,5,23]],"date-time":"2018-05-23T00:00:00Z","timestamp":1527033600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-4512-5","type":"journal-article","created":{"date-parts":[[2018,5,23]],"date-time":"2018-05-23T11:24:49Z","timestamp":1527074689000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Pulse actinomycin D as first-line treatment of low-risk post-molar non-choriocarcinoma gestational trophoblastic neoplasia"],"prefix":"10.1186","volume":"18","author":[{"given":"Lei","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xirun","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengzhi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tong","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junjun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9112-1021","authenticated-orcid":false,"given":"Yang","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,23]]},"reference":[{"issue":"11","key":"4512_CR1","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1038\/bjc.2012.462","volume":"107","author":"A Sita-Lumsden","year":"2012","unstructured":"Sita-Lumsden A, Short D, Lindsay I, Sebire NJ, Adjogatse D, Seckl MJ, Savage PM. Treatment outcomes for 618 women with gestational trophoblastic tumours following a molar pregnancy at the Charing cross hospital, 2000-2009. Br J Cancer. 2012;107(11):1810\u20134.","journal-title":"Br J Cancer"},{"issue":"3","key":"4512_CR2","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ygyno.2011.10.036","volume":"124","author":"L Eiriksson","year":"2012","unstructured":"Eiriksson L, Wells T, Steed H, Schepansky A, Capstick V, Hoskins P, Pike J, Swenerton K. Combined methotrexate-dactinomycin: an effective therapy for low-risk gestational trophoblastic neoplasia. Gynecol Oncol. 2012;124(3):553\u20137.","journal-title":"Gynecol Oncol"},{"issue":"7","key":"4512_CR3","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1200\/JCO.2010.30.4386","volume":"29","author":"RJ Osborne","year":"2011","unstructured":"Osborne RJ, Filiaci V, Schink JC, Mannel RS, Alvarez Secord A, Kelley JL, Provencher D, Scott Miller D, Covens AL, Lage JM. Phase III trial of weekly methotrexate or pulsed Dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study. J Clin Oncol. 2011;29(7):825\u201331.","journal-title":"J Clin Oncol"},{"issue":"2 Pt 1","key":"4512_CR4","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/0002-9378(95)90575-8","volume":"172","author":"JR Lurain","year":"1995","unstructured":"Lurain JR, Elfstrand EP. Single-agent methotrexate chemotherapy for the treatment of nonmetastatic gestational trophoblastic tumors. Am J Obstet Gynecol. 1995;172(2 Pt 1):574\u20139.","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"4512_CR5","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1016\/S0002-9378(96)70229-6","volume":"174","author":"JP Roberts","year":"1996","unstructured":"Roberts JP, Lurain JR. Treatment of low-risk metastatic gestational trophoblastic tumors with single-agent chemotherapy. Am J Obstet Gynecol. 1996;174(6):1917\u201323. discussion 23-4","journal-title":"Am J Obstet Gynecol"},{"issue":"10","key":"4512_CR6","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1200\/JCO.1996.14.10.2769","volume":"14","author":"GJ Rustin","year":"1996","unstructured":"Rustin GJ, Newlands ES, Lutz JM, Holden L, Bagshawe KD, Hiscox JG, Foskett M, Fuller S, Short D. Combination but not single-agent methotrexate chemotherapy for gestational trophoblastic tumors increases the incidence of second tumors. J Clin Oncol. 1996;14(10):2769\u201373.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4512_CR7","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/j.1479-828X.2005.00366.x","volume":"45","author":"MM Gilani","year":"2005","unstructured":"Gilani MM, Yarandi F, Eftekhar Z, Hanjani P. Comparison of pulse methotrexate and pulse dactinomycin in the treatment of low-risk gestational trophoblastic neoplasia. Aust N Z J Obstet Gynaecol. 2005;45(2):161\u20134.","journal-title":"Aust N Z J Obstet Gynaecol"},{"issue":"1","key":"4512_CR8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ijgo.2008.05.013","volume":"103","author":"F Yarandi","year":"2008","unstructured":"Yarandi F, Eftekhar Z, Shojaei H, Kanani S, Sharifi A, Hanjani P. Pulse methotrexate versus pulse actinomycin D in the treatment of low-risk gestational trophoblastic neoplasia. Int J Gynaecol Obstet. 2008;103(1):33\u20137.","journal-title":"Int J Gynaecol Obstet"},{"key":"4512_CR9","first-page":"CD007102","volume":"6","author":"TA Lawrie","year":"2016","unstructured":"Lawrie TA, Alazzam M, Tidy J, Hancock BW, Osborne R. First-line chemotherapy in low-risk gestational trophoblastic neoplasia. Cochrane Database Syst Rev. 2016;6:CD007102.","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl 1","key":"4512_CR10","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S0020-7292(03)90120-2","volume":"83","author":"HY Ngan","year":"2003","unstructured":"Ngan HY, Bender H, Benedet JL, Jones H, Montruccoli GC, Pecorelli S. Gestational trophoblastic neoplasia, FIGO 2000 staging and classification. Int J Gynaecol Obstet. 2003;83(Suppl 1):175\u20137.","journal-title":"Int J Gynaecol Obstet"},{"issue":"1","key":"4512_CR11","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/uog.11097","volume":"40","author":"P Cavoretto","year":"2012","unstructured":"Cavoretto P, Gentile C, Mangili G, Garavaglia E, Valsecchi L, Spagnolo D, Montoli S, Candiani M. Transvaginal ultrasound predicts delayed response to chemotherapy and drug resistance in stage I low-risk trophoblastic neoplasia. Ultrasound Obstet Gynecol. 2012;40(1):99\u2013105.","journal-title":"Ultrasound Obstet Gynecol"},{"key":"4512_CR12","unstructured":"Common terminology criteria for adverse events (CTCAE). v4.03 http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/ . Accessed 1 May 2016."},{"issue":"1","key":"4512_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ijgo.2011.08.003","volume":"116","author":"A Mousavi","year":"2012","unstructured":"Mousavi A, Cheraghi F, Yarandi F, Gilani MM, Shojaei H. Comparison of pulsed actinomycin D versus 5-day methotrexate for the treatment of low-risk gestational trophoblastic disease. Int J Gynaecol Obstet. 2012;116(1):39\u201342.","journal-title":"Int J Gynaecol Obstet"},{"key":"4512_CR14","first-page":"78","volume":"28","author":"N Shahbazian","year":"2014","unstructured":"Shahbazian N, Razi T, Razi S, Yazdanpanah L. Comparison of the efficacy of methotrexate and actinomycin D in the treatment of patients with stage I low risk gestational trophoblastic neoplasia (GTN). Med J Islam Repub Iran. 2014;28:78.","journal-title":"Med J Islam Repub Iran"},{"issue":"5","key":"4512_CR15","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s12094-014-1251-1","volume":"17","author":"H Al-Husaini","year":"2015","unstructured":"Al-Husaini H, Soudy H, Darwish A, Ahmed M, Eltigani A, Edesa W, Elhassan T, Omar A, Elghamry W, Al-Hashem H, et al. Gestational trophoblastic neoplasia: treatment outcomes from a single institutional experience. Clin Transl Oncol. 2015;17(5):409\u201315.","journal-title":"Clin Transl Oncol"},{"issue":"7\u20138","key":"4512_CR16","first-page":"283","volume":"57","author":"JR Lurain","year":"2012","unstructured":"Lurain JR, Chapman-Davis E, Hoekstra AV, Schink JC. Actinomycin D for methotrexate-failed low-risk gestational trophoblastic neoplasia. J Reprod Med. 2012;57(7\u20138):283\u20137.","journal-title":"J Reprod Med."},{"issue":"2","key":"4512_CR17","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.3802\/jgo.2017.28.e8","volume":"28","author":"YJ Lee","year":"2017","unstructured":"Lee YJ, Park JY, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT, Nam JH. Comparing and evaluating the efficacy of methotrexate and actinomycin D as first-line single chemotherapy agents in low risk gestational trophoblastic disease. J Gynecol Oncol. 2017;28(2):e8.","journal-title":"J Gynecol Oncol"},{"issue":"1","key":"4512_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ajog.2010.06.072","volume":"204","author":"JR Lurain","year":"2011","unstructured":"Lurain JR. Gestational trophoblastic disease II: classification and management of gestational trophoblastic neoplasia. Am J Obstet Gynecol. 2011;204(1):11\u20138.","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"4512_CR19","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1590\/SO100-720320150005366","volume":"37","author":"EM Uberti","year":"2015","unstructured":"Uberti EM, Fajardo Mdo C, da Cunha AG, Frota SS, Braga A, Ayub AC. Treatment of low-risk gestational trophoblastic neoplasia comparing biweekly eight-day methotrexate with folinic acid versus bolus-dose Actinomycin-D, among Brazilian women. Rev Bras Ginecol Obstet. 2015;37(6):258\u201365.","journal-title":"Rev Bras Ginecol Obstet"},{"issue":"5\u20136","key":"4512_CR20","first-page":"230","volume":"61","author":"AA Lertkhachonsuk","year":"2016","unstructured":"Lertkhachonsuk AA, Hanvoravongchai P. Comparison of cost-effectiveness between Actinomycin D versus methotrexate-Folinic acid in the treatment of low-risk gestational trophoblastic neoplasia. J Reprod Med. 2016;61(5\u20136):230\u20134.","journal-title":"J Reprod Med."},{"issue":"15","key":"4512_CR21","doi-asserted-by":"publisher","first-page":"3184","DOI":"10.1016\/j.ejca.2013.06.004","volume":"49","author":"F Taylor","year":"2013","unstructured":"Taylor F, Grew T, Everard J, Ellis L, Winter MC, Tidy J, Hancock BW, Coleman RE. The outcome of patients with low risk gestational trophoblastic neoplasia treated with single agent intramuscular methotrexate and oral folinic acid. Eur J Cancer. 2013;49(15):3184\u201390.","journal-title":"Eur J Cancer"},{"issue":"5","key":"4512_CR22","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/sj.bjc.6605529","volume":"102","author":"S McGrath","year":"2010","unstructured":"McGrath S, Short D, Harvey R, Schmid P, Savage PM, Seckl MJ. The management and outcome of women with post-hydatidiform mole \u2018low-risk\u2019 gestational trophoblastic neoplasia, but hCG levels in excess of 100 000 IU l (\u22121). Br J Cancer. 2010;102(5):810\u20134.","journal-title":"Br J Cancer"},{"issue":"8","key":"4512_CR23","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1093\/annonc\/mdq033","volume":"21","author":"B You","year":"2010","unstructured":"You B, Pollet-Villard M, Fronton L, Labrousse C, Schott AM, Hajri T, Girard P, Freyer G, Tod M, Tranchand B, et al. Predictive values of hCG clearance for risk of methotrexate resistance in low-risk gestational trophoblastic neoplasias. Ann Oncol. 2010;21(8):1643\u201350.","journal-title":"Ann Oncol"},{"issue":"9","key":"4512_CR24","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1038\/bjc.2013.123","volume":"108","author":"B You","year":"2013","unstructured":"You B, Harvey R, Henin E, Mitchell H, Golfier F, Savage PM, Tod M, Wilbaux M, Freyer G, Seckl MJ. Early prediction of treatment resistance in low-risk gestational trophoblastic neoplasia using population kinetic modelling of hCG measurements. Br J Cancer. 2013;108(9):1810\u20136.","journal-title":"Br J Cancer"},{"issue":"3","key":"4512_CR25","doi-asserted-by":"crossref","first-page":"646","DOI":"10.4103\/0973-1482.138199","volume":"10","author":"M Hasanzadeh","year":"2014","unstructured":"Hasanzadeh M, Tabari A, Homae F, Shakeri M, Bakhshandeh T, MadaniSani F. Evaluation of weekly intramuscular methotrexate in the treatment of low risk gestational trophoblastic neoplasia. J Cancer Res Ther. 2014;10(3):646\u201350.","journal-title":"J Cancer Res Ther"},{"issue":"1","key":"4512_CR26","doi-asserted-by":"publisher","first-page":"38","DOI":"10.4103\/0973-1482.110357","volume":"9","author":"MM Gilani","year":"2013","unstructured":"Gilani MM, Fariba B, Behtash N, Ghaemmaghami F, Moosavi AS, Rezayof E. The WHO score predicts treatment outcome in low risk gestational trophoblastic neoplasia patients treated with weekly intramuscular methotrexate. J Cancer Res Ther. 2013;9(1):38\u201343.","journal-title":"J Cancer Res Ther"},{"issue":"3","key":"4512_CR27","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.ygyno.2012.03.039","volume":"125","author":"E Chapman-Davis","year":"2012","unstructured":"Chapman-Davis E, Hoekstra AV, Rademaker AW, Schink JC, Lurain JR. Treatment of nonmetastatic and metastatic low-risk gestational trophoblastic neoplasia: factors associated with resistance to single-agent methotrexate chemotherapy. Gynecol Oncol. 2012;125(3):572\u20135.","journal-title":"Gynecol Oncol"},{"issue":"6","key":"4512_CR28","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/bjc.2012.65","volume":"106","author":"R Agarwal","year":"2012","unstructured":"Agarwal R, Harding V, Short D, Fisher RA, Sebire NJ, Harvey R, Patel D, Savage PM, Lim AK, Seckl MJ. Uterine artery pulsatility index: a predictor of methotrexate resistance in gestational trophoblastic neoplasia. Br J Cancer. 2012;106(6):1089\u201394.","journal-title":"Br J Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4512-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-4512-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4512-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T19:36:34Z","timestamp":1693683394000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-4512-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,23]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4512"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-4512-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,23]]},"assertion":[{"value":"5 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All women participated in the study voluntarily and gave written informed consent prior to study begin. They were informed that they can withdraw their consent and stop participation at any time without disclosing the reasons and without negative consequences for their future medical care. Institutional Review Board of Peking Union Medical College Hospital had approved this retrospective study (reference number ZS-1428).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"585"}}